# US 2012/0252736 A1 · Methods involving pdgfrbeta inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252736 A1
- Document ID: US20120252736A1
- Status: Published application
- Kind: A1
- Application number: 13/498,827
- Filed: 2010-09-28
- Published: 2012-10-04
- Earliest claimed: 2009-09-28
- Assignees: Medizinische Universitaet Wien
- Inventors: Lukas Kenner; Daniela Laimer
- Web page: https://patentgrep.com/patent/US20120252736A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention refers to PDGFRbeta inhibitor for use in the antiproliferative treatment of T-cell lymphoma, in particular NHL, ALCL and PTCL.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A method of treating a patient with T-cell lymphoma and susceptible to a cell proliferative disorder comprising:
obtaining a PDGFRbeta inhibitor; and
administering the PDGFRbeta inhibitor to the patient.

### Claim 17 (depends on 16)

The method of claim 16, wherein the patient has AP-1 expressing lymphoma.

### Claim 18 (depends on 16)

The method of claim 16, wherein the patient has NHL, ALCL, or PTCL.

### Claim 19 (depends on 18)

The method of claim 18, wherein the patient has ALK+-ALCL.

### Claim 20 (depends on 19)

The method of claim 19, wherein the patient has NPM-ALK+-ALCL.

### Claim 21 (depends on 16)

The method of claim 16, wherein the patient is in relapse.

### Claim 22 (depends on 16)

The method of claim 16, wherein the patient is in first line therapy.

### Claim 23 (depends on 16)

The method of claim 16, wherein the PDGFRbeta inhibitor is a PDGFRbeta antagonist.

### Claim 24 (depends on 23)

The method of claim 23, wherein the PDGFRbeta antagonist is a polypeptide or small molecule.

### Claim 25 (depends on 23)

The method of claim 23, wherein the PDGFRbeta antagonist is nilotinib, imatinib, dasatinib, axitinib, sunitinib, or toceranib.

### Claim 26 (depends on 16)

The method of claim 16, further defined as being a prophylactic treatment.

### Claim 27 (depends on 16)

The method of claim 16, further defined as being a therapeutic treatment.

### Claim 28 (depends on 16)

The method of claim 16, wherein the PDGFRbeta inhibitor is administered locally or systemically.

### Claim 29 (depends on 16)

The method of claim 16, wherein the PDGFRbeta inhibitor is administered orally.

### Claim 30 (depends on 29)

The method of claim 29, wherein the PDGFRbeta inhibitor is administered at a dose ranging from 0.001 mg/kg/day to about 100 mg/kg/day.

### Claim 31 (depends on 30)

The method of claim 30, wherein the PDGFRbeta inhibitor is administered in combination with chemotherapy and/or radiation therapy.

### Claim 32 (depends on 16)

The method of claim 16, further comprising determining whether tumor cells of the patient express AP-1 and/or ALK.

### Claim 33

A method comprising:
obtaining a PDGFRbeta inhibitor; and
using the PDGFRbeta inhibitor to prepare a pharmaceutical composition useful for treating a patient having T-cell lymphoma and susceptible to a cell proliferative disorder.
